The MDM2-inhibitor Nutlin-3 synergizes with cisplatin to induce p53 dependent tumor cell apoptosis in non-small cell lung cancer-Reference-Cited by-同舟云学术

The MDM2-inhibitor Nutlin-3 synergizes with cisplatin to induce p53 dependent tumor cell apoptosis in non-small cell lung cancer

Published:2015-06-10 Issue:26 Volume:6 Page:22666-22679
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Deben Christophe¹²,Wouters An¹,de Beeck Ken Op¹³,van Den Bossche Jolien¹,Jacobs Julie¹,Zwaenepoel Karen²,Peeters Marc¹⁴,Van Meerbeeck Jan⁵,Lardon Filip¹,Rolfo Christian⁴⁶,Deschoolmeester Vanessa¹²,Pauwels Patrick¹²

Affiliation:

1. Center for Oncological Research (CORE), University of Antwerp, Antwerp, Belgium

2. Department of Pathology, Antwerp University Hospital, Antwerp, Belgium

3. Center for Medical Genetics, Department of Biomedical Sciences, University of Antwerp, Antwerp, Belgium

4. Department of Medical Oncology, Antwerp University Hospital, Antwerp, Belgium

5. Department of Thoracic Oncology, Antwerp University Hospital, Antwerp, Belgium

6. Phase-1 Early Clinical Trials Unit, Antwerp University Hospital, Antwerp, Belgium

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 64 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Enzymatic Desymmetrisation of Prochiral meso-1,2-Disubstituted-1,2-Diaminoethane for the Synthesis of Key Enantioenriched (−)-Nutlin-3 Precursor;Molecules;2024-07-10

2. MDM2/MDMX inhibition by Sulanemadlin synergizes with anti-Programmed Death 1 immunotherapy in wild-type p53 tumors;iScience;2024-06

3. Discovery of Novel p53-MDM2 Inhibitor (RG7388)-Conjugated Platinum^IV Complexes as Potent Antitumor Agents;Journal of Medicinal Chemistry;2024-05-22

4. Precision Targeting of Non-Small Cell Lung Cancer: Identifying Optimal Drug Targets and FDA-Approved Combinations for Enhanced Therapeutic Efficacy;2023 IEEE 23rd International Conference on Bioinformatics and Bioengineering (BIBE);2023-12-04

5. Sirtuin1-p53: A potential axis for cancer therapy;Biochemical Pharmacology;2023-06